Indication intelligence, analysis and sector perception

RegMed's close: a sector with its tail between its legs, feed the dog and he will wag

September 22, 2015 6:18pm

The stem, cell, gene therapy and regenerative medicine (SCGT & RM) equities are always afraid about something – drug pricing and its ramifications are just an excuse!

Have you missed me and today’s close updates? Subscribe: http://www.regmedinvestors.com/user/register

Stocks mention in the closing bell report: StemCells (STEM), bluebird bio (BLUE), Regenxbio (RGNX), Intrexon (XON), Organovo (ONVO), Regenxbio (RGNX), Neuralstem (CUR), Cesca Therapeutics (KOOL), Spark Therapeutics (ONCE), VistaGen (VSTA), Athersys (ATHX), uniQure (QURE), Brainstorm (BCLI), Fate Therapeutics (FATE) and Kite Pharma (KITE),

Stocks pared losses in the last hour of trade Tuesday to close off their session lows. The Dow ended down 1.1%, the S&P 500 shed 1.2% and the NASDAQ fell 1.5%. Volume was mixed, running higher on the NYSE and lower on the NASDAQ.

The NASDAQ closed DOWN -72.23 or -1.50% to 4,756.72 and the DOW was also DOWN -179.72 or -1.09% to 16,330.47.

A day in the life of the stem, cell and gene therapy RegMed SCGT & RM sector and market:

Volume is particularly light in regard to the pricing turndown!

A dog does some of its talking with its tail. It's an important piece of her body language, helping communicate moods and feelings.

The stem, cell, gene therapy and regenerative medicine (SCGT & RM) equities opened with a negative A/DL of 8/33 and 2 flats followed by a negative mid-day A/DL of 6/36 and 1 flat.

There's a "confluence” of negative inputs taking us close to technical <bottom?> levels!

The 3 pm hour solidified a negative A/DL of 3/38 and 2 flats culminating in Tuesday’s tumultuous close with a negative A/DL of 7/33 and 3 flat.

The iShares Nasdaq Biotechnology ETF (IBB) fell more than 3% in afternoon trade after posting its worst day of 2015 Monday.

The CBOE Volatility Index (.VIX), widely considered the best gauge of fear in the market, ticked higher to trade above 23.5.

“Our” universe has been walking a tightrope in the past two days, but it still needs to use its “tail” <past pricing> for balance. Some sector “participants” need their news to … wag its tails when they announce releases; without support and tails, their back end does not follow their front ends around tight range and obstacle pricing corners.

Dosing the sector – 43 Patients:

Open: NEGATIVE with 33 decliners, 8 advancers and 2 flats;

1st hour (10:30 am): NEGATIVE 35 decliners, 7 advancers and 1 flat;

2nd hour (11:30 am): NEGATIVE with 38 decliners, 4 advancers and 1 flat;

Mid-day (12:30 pm) NEGATIVE with 36 decliners, 6 advancers and 1 flat;

3 pm: NEGATIVE with 38 decliners, 3 advancers and 2 flats;

Closing bell: NEGATIVE with 33 decliners, 7 advancers and 3 flats

The week’s indexes in review:

The iShares Nasdaq Biotechnology ETF (IBB) closed DOWN -5.07 or -1.49% on Tuesday after Monday’s decline of -16.29 or – 4.57%;

The Russell 2000 (IWM) closed DOWN on Tuesday -1.75 or -1.52% after Monday’s decline of -0.21 or -0.18%;

The SPDR SD&P Biotech ETF (XBI) closed DOWN on Tuesday -1.63 or -2.17% after Monday’s decline of -4.28 or -5.39%;

The CBOE Volatility Index (.VIX) closed Tuesday at 23.5 after Monday’s below 22

A comparison of the closing bell patterns of advance/decline lines:

Last, Tuesday: 32/10;

Wednesday: 23/19;

Thursday: 30/9;

Friday: 27/15;

Monday: 6/35;

Today, Tuesday: 7/33

Who is down – lowest 5?

bluebird bio (BLUE) was down -$7.60 to $119.84;

Regenxbio (RGNX) -$3.76 to $26.05;

Spark Therapeutics (ONCE) -$1.73 to $43.26;

uniQure (QURE) -$1.51 to $27.58;

Intrexon (XON) was down -$1.40 to $45.98;

Who is UP – the only “7”?

Capricor (CAPR) was up +$0.10 to $4.60;

Organovo (ONVO) +$0.13 to $3.76;

Kite Pharma (KITE) +$0.08 to $61.34;

Neuralstem (CUR) +$0.05 to $1.56;

Cesca Therapeutics (KOOL) +$0.01 to $0.66;

Athersys (ATHX) +$0.01 to $1.35;

Fate Therapeutics (FATE) was up +$0.01 to $6.91

Who is flat?

Brainstorm (BCLI) at $3.13;

StemCells (STEM) at $0.53;

VistaGen (VSTA) at $9.25

I bring fresh perspectives that yield a whole that is greater than the sum of the parts as I convey a spectrum of factors that explain outcomes, analytical principles and analysis without the encumbrance of I-Banking.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities as referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.